- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals | 3 | Seeking Alpha | ||
| 13.05. | Journey Medical: Starker Gewinn pro Aktie, aber Umsatz enttäuscht | 9 | Investing.com Deutsch | ||
| 13.05. | Transcript: Journey Medical Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.05. | Journey Medical: EPS übertrifft Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 13.05. | Journey Medical Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 253 | GlobeNewswire (Europe) | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.04. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi | 2 | GlobeNewswire (USA) | ||
| 26.03. | Journey Medical stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com | ||
| 26.03. | Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand | 2 | Seeking Alpha | ||
| 25.03. | Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M | 1 | Seeking Alpha | ||
| 25.03. | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | 370 | GlobeNewswire (Europe) | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| 25.03. | Journey Medical Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 18.03. | Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 04.02. | B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target | 2 | Investing.com | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 334 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 693 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,100 | +0,59 % | RBC stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Pfizer mit einem Kursziel von 25 US-Dollar auf "Sector Perform" belassen. Seine Umsatzschätzung entspreche dem Konsens, schrieb... ► Artikel lesen | |
| GILEAD SCIENCES | 119,98 | +0,72 % | Wenn die großen Pharmakonzerne Milliarden in Krebs investieren - entsteht der nächste Zelltherapie-Boom ganz woanders? | ||
| ELI LILLY | 1.025,20 | +0,25 % | Nach der Rallye: Die UBS nennt neue Börsenfavoriten - und es sind keine KI-Aktien | © Foto: wallstreetonline/KI - OpenAINach der starken Börsenrallye rät die UBS zu defensiven Aktien mit stabilen Geschäften. Warum gerade diese Titel jetzt interessant sein könnten.Nach einem starken... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 426,80 | +0,45 % | Biotech- und Pharma-Aktien drehen auf: Das Milliarden-Beben bei Bayer und Vertex rückt diesen Small-Cap ins Rampenlicht | ||
| INNOCAN PHARMA | 1,930 | +6,63 % | InnoCan Pharma sendet Krisensignal: Das Warnsignal das die meisten Anleger jetzt übersehen - Was erfahrene Trader jetzt tun | ||
| EYEPOINT | 11,600 | +1,75 % | EyePoint, Inc.: EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer | WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 205,30 | -3,02 % | AbCellera Biologics Inc.: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 258,00 | +0,78 % | Benchmark erhöht Kursziel für Ligand Pharma nach XOMA-Deal auf 335 $ | ||
| OPKO HEALTH | 1,030 | -1,90 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| UNITED THERAPEUTICS | 468,50 | +1,34 % | UNITED THERAPEUTICS Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| JAGUAR HEALTH | 1,335 | 0,00 % | Jaguar Health, Inc. - 8-K, Current Report | ||
| ROYALTY PHARMA | 50,30 | -1,68 % | Royalty Pharma plc: Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 | ||
| CATALYST PHARMACEUTICALS | 27,500 | -0,36 % | XFRA CN2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCATALYST PHARM.INC.DL-001... ► Artikel lesen | |
| TG THERAPEUTICS | 45,900 | -4,38 % | TG Therapeutics, Inc.: TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia | NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 68,58 | -2,34 % | H.C. Wainwright hebt Kursziel für BridgeBio nach Rückschlag für Konkurrenten auf 120 $ an |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,14 % bei einem Aktienkurs von 7,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.